111 – 120 of 362
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Domain-adversarial neural network for improved generalization performance of gleason grade classification
2020) Medical Imaging 2020: Digital Pathology In Progress in Biomedical Optics and Imaging - Proceedings of SPIE 11320.(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2019
-
Mark
Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy
(
- Contribution to journal › Article
-
Mark
90-Day readmission after radical prostatectomy—a prospective comparison between robot-assisted and open surgery
(
- Contribution to journal › Article
-
Mark
Expression of tSTAT3, pSTAT3
727
, and pSTAT3
705
in the epithelial cells of hormone-naïve prostate cancer
(
- Contribution to journal › Article
-
Mark
Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE) : a cost minimisation analysis
(
- Contribution to journal › Article
-
Mark
Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer
(
- Contribution to journal › Article
-
Mark
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
(
- Contribution to journal › Article
-
Mark
A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
(
- Contribution to journal › Article
-
Mark
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
(
- Contribution to journal › Article
-
Mark
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study
(
- Contribution to journal › Article